A community-based comprehensive intervention to reduce cardiovascular risk in hypertension (HOPE 4): a cluster-randomised controlled trial
Background: Hypertension is the leading cause of cardiovascular disease globally. Despite proven benefits, hypertension control is poor. We hypothesised that a comprehensive approach to lowering blood pressure and other risk factors, informed by detailed analysis of local barriers, would be superior...
Published in: | The Lancet |
---|---|
Main Author: | Schwalm J.-D.; McCready T.; Lopez-Jaramillo P.; Yusoff K.; Attaran A.; Lamelas P.; Camacho P.A.; Majid F.; Bangdiwala S.I.; Thabane L.; Islam S.; McKee M.; Yusuf S. |
Format: | Article |
Language: | English |
Published: |
Lancet Publishing Group
2019
|
Online Access: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85072785863&doi=10.1016%2fS0140-6736%2819%2931949-X&partnerID=40&md5=49680f916069c50ffd22e8a44ec6b35b |
Similar Items
-
Rationale and design of a cluster randomized trial of a multifaceted intervention in people with hypertension: The Heart Outcomes Prevention and Evaluation 4 (HOPE-4) Study
by: Schwalm J.-D.R.; McCready T.; Lamelas P.; Musa H.; Lopez-Jaramillo P.; Yusoff K.; McKee M.; Camacho P.A.; Lopez-Lopez J.; Majid F.; Thabane L.; Islam S.; Yusuf S.
Published: (2018) -
Community-based cardiovascular risk factors intervention strategies (CORFIS) in managing hypertension: A pragmatic non-randomised controlled trial
by: Low W.H.H.; Seet W.; Ramli A.S.; Ng K.K.; Jamaiyah H.; Dan S.P.; Teng C.L.; Lee V.K.M.; Chua S.S.; Faridah Aryani M.Y.; Karupaiah T.; Chee W.S.S.; Goh P.P.; Zaki M.; Lim T.
Published: (2013) -
Effectiveness of the EMPOWER-PAR Intervention in Improving Clinical Outcomes of Type 2 Diabetes Mellitus in Primary Care: A Pragmatic Cluster Randomised Controlled Trial
by: Ramli A.S.; Selvarajah S.; Daud M.H.; Haniff J.; Abdul-Razak S.; Tg-Abu-Bakar-Sidik T.M.I.; Bujang M.A.; Chew B.H.; Rahman T.; Tong S.F.; Shafie A.A.; Lee V.K.M.; Ng K.K.; Ariffin F.; Abdul-Hamid H.; Mazapuspavina M.Y.; Mat-Nasir N.; Chan C.W.; Yong-Rafidah A.R.; Ismail M.; Lakshmanan S.; Low W.H.H.
Published: (2016) -
A partially randomised trial of pretomanid, moxifloxacin and pyrazinamide for pulmonary TB
by: Tweed C.D.; Wills G.H.; Crook A.M.; Amukoye E.; Balanag V.; Ban A.Y.L.; Bateson A.L.C.; Betteridge M.C.; Brumskine W.; Caoili J.; Chaisson R.E.; Cevik M.; Conradie F.; Dawson R.; del Parigi A.; Diacon A.; Everitt D.E.; Fabiane S.M.; Hunt R.; Ismail A.I.; Lalloo U.; Lombard L.; Louw C.; Malahleha M.; McHugh T.D.; Mendel C.M.; Mhimbira F.; Moodliar R.N.; Nduba V.; Nunn A.J.; Sabi I.; Sebe M.A.; Selepe R.A.P.; Staples S.; Swindells S.; van Niekerk C.H.; Variava E.; Spigelman M.; Gillespie S.H.
Published: (2021) -
Novel Approaches in Primary Cardiovascular Disease Prevention: The HOPE-3 Trial Rationale, Design, and Participants' Baseline Characteristics
by: Lonn E.; Bosch J.; Pogue J.; Avezum A.; Chazova I.; Dans A.; Diaz R.; Fodor G.J.; Held C.; Jansky P.; Keltai M.; Keltai K.; Kunti K.; Kim J.-H.; Leiter L.; Lewis B.; Liu L.; Lopez-Jaramillo P.; Pais P.; Parkhomenko A.; Peters R.J.G.; Piegas L.S.; Reid C.M.; Sliwa K.; Toff W.D.; Varigos J.; Xavier D.; Yusoff K.; Zhu J.; Dagenais G.; Yusuf S.
Published: (2016)